Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (358)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03734068 | Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC(LIFDOX) | unknown | — | 100 | International Group of Endovascular OncologyOTHER | 1 | Feb 21, 2019 | clinicaltrials |
| NCT00465842 | Protein Biomarker in Hepatocellular Carcinoma | terminated | — | 211 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 |
| Feb 15, 2019 |
| clinicaltrials |
| NCT02748304 | Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma | terminated | N/A | 52 | Fudan UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01619475 | Adult-to-Adult Living Donor Transplant Cohort Study(A2ALL-2) | completed | — | 1,871 | Arbor Research Collaborative for HealthOTHER | 2 | Feb 8, 2019 | clinicaltrials |
| NCT00441376 | A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver | completed | Phase 1 | 30 | ImunonINDUSTRY | 1 | Feb 7, 2019 | clinicaltrials |
| NCT03313596 | Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC | unknown | Phase 3 | 180 | Huazhong University of Science and TechnologyOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT00946153 | Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 66 | Eisai Co., Ltd.INDUSTRY | 2 | Feb 1, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT01306058 | Sorafenib and TRC105 in Hepatocellular Cancer | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01600196 | Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus | terminated | Phase 4 | 126 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03614546 | Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma | unknown | N/A | 200 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03812783 | HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03807947 | Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma | unknown | N/A | 74 | Humanitas Clinical and Research CenterOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT02191878 | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 43 | Arbutus Biopharma CorporationINDUSTRY | 6 | Jan 16, 2019 | clinicaltrials |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial | terminated | Phase 2 / Phase 3 | 79 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01210495 | Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma | completed | Phase 2 | 224 | PfizerINDUSTRY | 13 | Jan 9, 2019 | clinicaltrials |
| NCT03176485 | Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors | completed | N/A | 45 | University of ArizonaOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT03793322 | The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma | unknown | Phase 1 | 100 | Zhujiang HospitalOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT03793725 | A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC(HZ-T-PD1-APA) | unknown | Phase 2 | 30 | Yanqiao ZhangOTHER | 0 | Jan 4, 2019 | clinicaltrials |
| NCT03116945 | Novel Gallium Imaging in Hepatocellular Carcinoma | unknown | Phase 2 | 18 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03775395 | HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC | unknown | Phase 3 | 250 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03730675 | Irradiation Stent Placement Plus TACE for HCC and PVTT | unknown | N/A | 308 | Zhongda HospitalOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT03722875 | SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery | unknown | N/A | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03777475 | the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma | unknown | N/A | 350 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2018 | clinicaltrials |
| NCT00243841 | Dose Escalation Study for Primary Hepatocellular Carcinoma(SBF-HCC) | completed | N/A | 77 | Indiana UniversityOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT02073435 | A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation | completed | — | 177 | Northwestern UniversityOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT02069041 | A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer | completed | Phase 1 | 8 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02649712 | Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction | completed | N/A | 72 | Xuzhou Central HospitalOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT02719782 | A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation | unknown | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03732547 | Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT00827723 | Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma | completed | — | 60 | University of Lausanne HospitalsOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03739164 | Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)(TAMLAPS) | unknown | — | 10 | Florida Hospital Tampa Bay DivisionOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT01933945 | Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib(OPTIMIS) | completed | — | 1,676 | BayerINDUSTRY | 31 | Nov 6, 2018 | clinicaltrials |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | terminated | Phase 1 / Phase 2 | 1 | Taiwan Liposome CompanyINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02269995 | Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma | completed | — | 300 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 5, 2018 | clinicaltrials |
| NCT03722628 | The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC | unknown | — | 200 | Assiut UniversityOTHER | 0 | Oct 29, 2018 | clinicaltrials |
| NCT03668158 | Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma | unknown | — | 500 | Zhejiang UniversityOTHER | 0 | Oct 24, 2018 | clinicaltrials |
| NCT03708705 | Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective Study | unknown | — | 500 | Zhejiang UniversityOTHER | 0 | Oct 19, 2018 | clinicaltrials |
| NCT02787954 | Prospective Tumor Response Evaluation(Liver) | terminated | — | 10 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT02833298 | Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening | completed | N/A | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT01360255 | AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE) | completed | — | 70 | University Hospital FreiburgOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT03698643 | Impact of New Interventional Imaging Modality Use on Patient Radiation Exposure in Transarterial Chemoembolization | completed | — | 145 | University Hospital, MontpellierOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03686709 | Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment | recruiting | N/A | 20 | University of TennesseeOTHER | 1 | Sep 27, 2018 | clinicaltrials |
| NCT01395030 | PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection | completed | Phase 2 | 64 | Queen's Medical CenterOTHER | 1 | Sep 26, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Feb 21, 2019source: clinicaltrials